Log in

OTCMKTS:FSDDFFSD Pharma Stock Price, Forecast & News

$3.06
-0.71 (-18.83 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.75
Now: $3.06
$3.76
50-Day Range
$2.55
MA: $4.36
$6.00
52-Week Range
$3.43
Now: $3.06
$68.66
Volume73,323 shs
Average Volume6,994 shs
Market Capitalization$23.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of the indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for various central nervous system disorders, including chronic pain, fibromyalgia, and irritable bowel syndrome. It has a strategic alliance agreement with SciCann Therapeutics Inc. for the production and distribution of cannabinoid-based, patent pending, and indication-specific products. FSD Pharma Inc. is headquartered in Cobourg, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:FSDDF
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$70,000.00

Profitability

Miscellaneous

EmployeesN/A
Market Cap$23.19 million
Next Earnings DateN/A
OptionableNot Optionable

Receive FSDDF News and Ratings via Email

Sign-up to receive the latest news and ratings for FSDDF and its competitors with MarketBeat's FREE daily newsletter.


FSD Pharma (OTCMKTS:FSDDF) Frequently Asked Questions

How has FSD Pharma's stock been impacted by COVID-19 (Coronavirus)?

FSD Pharma's stock was trading at $4.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FSDDF stock has decreased by 28.0% and is now trading at $3.06. View which stocks have been mosted impacted by Coronavirus.

Has FSD Pharma been receiving favorable news coverage?

News articles about FSDDF stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. FSD Pharma earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutFSD Pharma.

Who are some of FSD Pharma's key competitors?

What other stocks do shareholders of FSD Pharma own?

Who are FSD Pharma's key executives?

FSD Pharma's management team includes the following people:
  • Mr. Anthony John Durkacz, Founder & Co-Chairman (Age 43)
  • Dr. Raza Bokhari M.B.A., MBA, Exec. Co-Chairman & Interim CEO (Age 51)
  • Mr. Zeeshan Saeed, Founder, Pres & Director
  • Mr. Donal Carroll, Interim CFO
  • Dr. Sara May, Pres of FV Pharma

What is FSD Pharma's stock symbol?

FSD Pharma trades on the OTCMKTS under the ticker symbol "FSDDF."

How do I buy shares of FSD Pharma?

Shares of FSDDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FSD Pharma's stock price today?

One share of FSDDF stock can currently be purchased for approximately $3.06.

How big of a company is FSD Pharma?

FSD Pharma has a market capitalization of $23.19 million and generates $70,000.00 in revenue each year.  View additional information about FSD Pharma.

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: Green Investing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel